 | • レポートコード：MRC2-11QY12253 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はヒトマイクロバイオームベース薬剤・診断のグローバル市場について調査・分析したレポートです。種類別（治療、診断）市場規模、用途別（臨床研究所、病院、外科センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別ヒトマイクロバイオームベース薬剤・診断の競争状況、市場シェア ・世界のヒトマイクロバイオームベース薬剤・診断市場：種類別市場規模 2015年-2020年（治療、診断） ・世界のヒトマイクロバイオームベース薬剤・診断市場：種類別市場規模予測 2021年-2026年（治療、診断） ・世界のヒトマイクロバイオームベース薬剤・診断市場：用途別市場規模 2015年-2020年（臨床研究所、病院、外科センター、その他） ・世界のヒトマイクロバイオームベース薬剤・診断市場：用途別市場規模予測 2021年-2026年（臨床研究所、病院、外科センター、その他） ・北米のヒトマイクロバイオームベース薬剤・診断市場分析：米国、カナダ ・ヨーロッパのヒトマイクロバイオームベース薬剤・診断市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのヒトマイクロバイオームベース薬剤・診断市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のヒトマイクロバイオームベース薬剤・診断市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのヒトマイクロバイオームベース薬剤・診断市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Second Genome、Enterome Bioscience、Yakult、Dowdupont、Vedanta BioSciences、Metabiomics Corporation、ViThera Pharmaceuticals、MicroBiome Therapeutics、Osel、Merck ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
The modern approach involves exploiting the interaction between humans and the bacteria that live in or on the body to develop new drugs and therapies to treat chronic diseases such as diabetes. These microbiomes derived drugs help the physician in better diagnosis of the illness.
Rising cases of chronic diseases such as diabetes, disorders at early stage and the ability of the drugs to diagnose them and increased awareness among people to maintain healthy lifestyle is driving the growth of this market.
Market Analysis and Insights: Global Human Microbiome Based Drugs and Diagnostics Market
The global Human Microbiome Based Drugs and Diagnostics market size is projected to reach US$ 920.3 million by 2026, from US$ 827.9 million in 2020, at a CAGR of 10.3%% during 2021-2026.
Global Human Microbiome Based Drugs and Diagnostics Scope and Market Size
Human Microbiome Based Drugs and Diagnostics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Human Microbiome Based Drugs and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Second Genome
Enterome Bioscience
Yakult
Dowdupont
Vedanta BioSciences
Metabiomics Corporation
ViThera Pharmaceuticals
MicroBiome Therapeutics
Osel
Merck
Market segment by Type, the product can be split into
Therapeutics
Diagnostics
Market segment by Application, split into
Clinical Research Institutes
Hospital
Surgical Centers
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Human Microbiome Based Drugs and Diagnostics Revenue
1.4 Market by Type
1.4.1 Global Human Microbiome Based Drugs and Diagnostics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Therapeutics
1.4.3 Diagnostics
1.5 Market by Application
1.5.1 Global Human Microbiome Based Drugs and Diagnostics Market Share by Application: 2020 VS 2026
1.5.2 Clinical Research Institutes
1.5.3 Hospital
1.5.4 Surgical Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Human Microbiome Based Drugs and Diagnostics Market Perspective (2015-2026)
2.2 Global Human Microbiome Based Drugs and Diagnostics Growth Trends by Regions
2.2.1 Human Microbiome Based Drugs and Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Human Microbiome Based Drugs and Diagnostics Historic Market Share by Regions (2015-2020)
2.2.3 Human Microbiome Based Drugs and Diagnostics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Human Microbiome Based Drugs and Diagnostics Market Growth Strategy
2.3.6 Primary Interviews with Key Human Microbiome Based Drugs and Diagnostics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Human Microbiome Based Drugs and Diagnostics Players by Market Size
3.1.1 Global Top Human Microbiome Based Drugs and Diagnostics Players by Revenue (2015-2020)
3.1.2 Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Players (2015-2020)
3.1.3 Global Human Microbiome Based Drugs and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Human Microbiome Based Drugs and Diagnostics Market Concentration Ratio
3.2.1 Global Human Microbiome Based Drugs and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Human Microbiome Based Drugs and Diagnostics Revenue in 2019
3.3 Human Microbiome Based Drugs and Diagnostics Key Players Head office and Area Served
3.4 Key Players Human Microbiome Based Drugs and Diagnostics Product Solution and Service
3.5 Date of Enter into Human Microbiome Based Drugs and Diagnostics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Human Microbiome Based Drugs and Diagnostics Historic Market Size by Type (2015-2020)
4.2 Global Human Microbiome Based Drugs and Diagnostics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020)
5.2 Global Human Microbiome Based Drugs and Diagnostics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Human Microbiome Based Drugs and Diagnostics Market Size (2015-2020)
6.2 Human Microbiome Based Drugs and Diagnostics Key Players in North America (2019-2020)
6.3 North America Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020)
6.4 North America Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Human Microbiome Based Drugs and Diagnostics Market Size (2015-2020)
7.2 Human Microbiome Based Drugs and Diagnostics Key Players in Europe (2019-2020)
7.3 Europe Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020)
7.4 Europe Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020)
8 China
8.1 China Human Microbiome Based Drugs and Diagnostics Market Size (2015-2020)
8.2 Human Microbiome Based Drugs and Diagnostics Key Players in China (2019-2020)
8.3 China Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020)
8.4 China Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Human Microbiome Based Drugs and Diagnostics Market Size (2015-2020)
9.2 Human Microbiome Based Drugs and Diagnostics Key Players in Japan (2019-2020)
9.3 Japan Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020)
9.4 Japan Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Size (2015-2020)
10.2 Human Microbiome Based Drugs and Diagnostics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020)
10.4 Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020)
11 India
11.1 India Human Microbiome Based Drugs and Diagnostics Market Size (2015-2020)
11.2 Human Microbiome Based Drugs and Diagnostics Key Players in India (2019-2020)
11.3 India Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020)
11.4 India Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Human Microbiome Based Drugs and Diagnostics Market Size (2015-2020)
12.2 Human Microbiome Based Drugs and Diagnostics Key Players in Central & South America (2019-2020)
12.3 Central & South America Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020)
12.4 Central & South America Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Second Genome
13.1.1 Second Genome Company Details
13.1.2 Second Genome Business Overview
13.1.3 Second Genome Human Microbiome Based Drugs and Diagnostics Introduction
13.1.4 Second Genome Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020))
13.1.5 Second Genome Recent Development
13.2 Enterome Bioscience
13.2.1 Enterome Bioscience Company Details
13.2.2 Enterome Bioscience Business Overview
13.2.3 Enterome Bioscience Human Microbiome Based Drugs and Diagnostics Introduction
13.2.4 Enterome Bioscience Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020)
13.2.5 Enterome Bioscience Recent Development
13.3 Yakult
13.3.1 Yakult Company Details
13.3.2 Yakult Business Overview
13.3.3 Yakult Human Microbiome Based Drugs and Diagnostics Introduction
13.3.4 Yakult Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020)
13.3.5 Yakult Recent Development
13.4 Dowdupont
13.4.1 Dowdupont Company Details
13.4.2 Dowdupont Business Overview
13.4.3 Dowdupont Human Microbiome Based Drugs and Diagnostics Introduction
13.4.4 Dowdupont Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020)
13.4.5 Dowdupont Recent Development
13.5 Vedanta BioSciences
13.5.1 Vedanta BioSciences Company Details
13.5.2 Vedanta BioSciences Business Overview
13.5.3 Vedanta BioSciences Human Microbiome Based Drugs and Diagnostics Introduction
13.5.4 Vedanta BioSciences Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020)
13.5.5 Vedanta BioSciences Recent Development
13.6 Metabiomics Corporation
13.6.1 Metabiomics Corporation Company Details
13.6.2 Metabiomics Corporation Business Overview
13.6.3 Metabiomics Corporation Human Microbiome Based Drugs and Diagnostics Introduction
13.6.4 Metabiomics Corporation Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020)
13.6.5 Metabiomics Corporation Recent Development
13.7 ViThera Pharmaceuticals
13.7.1 ViThera Pharmaceuticals Company Details
13.7.2 ViThera Pharmaceuticals Business Overview
13.7.3 ViThera Pharmaceuticals Human Microbiome Based Drugs and Diagnostics Introduction
13.7.4 ViThera Pharmaceuticals Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020)
13.7.5 ViThera Pharmaceuticals Recent Development
13.8 MicroBiome Therapeutics
13.8.1 MicroBiome Therapeutics Company Details
13.8.2 MicroBiome Therapeutics Business Overview
13.8.3 MicroBiome Therapeutics Human Microbiome Based Drugs and Diagnostics Introduction
13.8.4 MicroBiome Therapeutics Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020)
13.8.5 MicroBiome Therapeutics Recent Development
13.9 Osel
13.9.1 Osel Company Details
13.9.2 Osel Business Overview
13.9.3 Osel Human Microbiome Based Drugs and Diagnostics Introduction
13.9.4 Osel Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020)
13.9.5 Osel Recent Development
13.10 Merck
13.10.1 Merck Company Details
13.10.2 Merck Business Overview
13.10.3 Merck Human Microbiome Based Drugs and Diagnostics Introduction
13.10.4 Merck Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020)
13.10.5 Merck Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Human Microbiome Based Drugs and Diagnostics Key Market Segments
Table 2. Key Players Covered: Ranking by Human Microbiome Based Drugs and Diagnostics Revenue
Table 3. Ranking of Global Top Human Microbiome Based Drugs and Diagnostics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Human Microbiome Based Drugs and Diagnostics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Therapeutics
Table 6. Key Players of Diagnostics
Table 7. Global Human Microbiome Based Drugs and Diagnostics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Human Microbiome Based Drugs and Diagnostics Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Human Microbiome Based Drugs and Diagnostics Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Human Microbiome Based Drugs and Diagnostics Market Share by Regions (2015-2020)
Table 11. Global Human Microbiome Based Drugs and Diagnostics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Human Microbiome Based Drugs and Diagnostics Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Human Microbiome Based Drugs and Diagnostics Market Growth Strategy
Table 17. Main Points Interviewed from Key Human Microbiome Based Drugs and Diagnostics Players
Table 18. Global Human Microbiome Based Drugs and Diagnostics Revenue by Players (2015-2020) (Million US$)
Table 19. Global Human Microbiome Based Drugs and Diagnostics Market Share by Players (2015-2020)
Table 20. Global Top Human Microbiome Based Drugs and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Microbiome Based Drugs and Diagnostics as of 2019)
Table 21. Global Human Microbiome Based Drugs and Diagnostics by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Human Microbiome Based Drugs and Diagnostics Product Solution and Service
Table 24. Date of Enter into Human Microbiome Based Drugs and Diagnostics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 27. Global Human Microbiome Based Drugs and Diagnostics Market Size Share by Type (2015-2020)
Table 28. Global Human Microbiome Based Drugs and Diagnostics Revenue Market Share by Type (2021-2026)
Table 29. Global Human Microbiome Based Drugs and Diagnostics Market Size Share by Application (2015-2020)
Table 30. Global Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 31. Global Human Microbiome Based Drugs and Diagnostics Market Size Share by Application (2021-2026)
Table 32. North America Key Players Human Microbiome Based Drugs and Diagnostics Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Human Microbiome Based Drugs and Diagnostics Market Share (2019-2020)
Table 34. North America Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 35. North America Human Microbiome Based Drugs and Diagnostics Market Share by Type (2015-2020)
Table 36. North America Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 37. North America Human Microbiome Based Drugs and Diagnostics Market Share by Application (2015-2020)
Table 38. Europe Key Players Human Microbiome Based Drugs and Diagnostics Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Human Microbiome Based Drugs and Diagnostics Market Share (2019-2020)
Table 40. Europe Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Human Microbiome Based Drugs and Diagnostics Market Share by Type (2015-2020)
Table 42. Europe Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Human Microbiome Based Drugs and Diagnostics Market Share by Application (2015-2020)
Table 44. China Key Players Human Microbiome Based Drugs and Diagnostics Revenue (2019-2020) (Million US$)
Table 45. China Key Players Human Microbiome Based Drugs and Diagnostics Market Share (2019-2020)
Table 46. China Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 47. China Human Microbiome Based Drugs and Diagnostics Market Share by Type (2015-2020)
Table 48. China Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 49. China Human Microbiome Based Drugs and Diagnostics Market Share by Application (2015-2020)
Table 50. Japan Key Players Human Microbiome Based Drugs and Diagnostics Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Human Microbiome Based Drugs and Diagnostics Market Share (2019-2020)
Table 52. Japan Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Human Microbiome Based Drugs and Diagnostics Market Share by Type (2015-2020)
Table 54. Japan Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Human Microbiome Based Drugs and Diagnostics Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Human Microbiome Based Drugs and Diagnostics Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Human Microbiome Based Drugs and Diagnostics Market Share (2019-2020)
Table 58. Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Share by Type (2015-2020)
Table 60. Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Share by Application (2015-2020)
Table 62. India Key Players Human Microbiome Based Drugs and Diagnostics Revenue (2019-2020) (Million US$)
Table 63. India Key Players Human Microbiome Based Drugs and Diagnostics Market Share (2019-2020)
Table 64. India Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 65. India Human Microbiome Based Drugs and Diagnostics Market Share by Type (2015-2020)
Table 66. India Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 67. India Human Microbiome Based Drugs and Diagnostics Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Human Microbiome Based Drugs and Diagnostics Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Human Microbiome Based Drugs and Diagnostics Market Share (2019-2020)
Table 70. Central & South America Human Microbiome Based Drugs and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Human Microbiome Based Drugs and Diagnostics Market Share by Type (2015-2020)
Table 72. Central & South America Human Microbiome Based Drugs and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Human Microbiome Based Drugs and Diagnostics Market Share by Application (2015-2020)
Table 74. Second Genome Company Details
Table 75. Second Genome Business Overview
Table 76. Second Genome Product
Table 77. Second Genome Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020) (Million US$)
Table 78. Second Genome Recent Development
Table 79. Enterome Bioscience Company Details
Table 80. Enterome Bioscience Business Overview
Table 81. Enterome Bioscience Product
Table 82. Enterome Bioscience Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020) (Million US$)
Table 83. Enterome Bioscience Recent Development
Table 84. Yakult Company Details
Table 85. Yakult Business Overview
Table 86. Yakult Product
Table 87. Yakult Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020) (Million US$)
Table 88. Yakult Recent Development
Table 89. Dowdupont Company Details
Table 90. Dowdupont Business Overview
Table 91. Dowdupont Product
Table 92. Dowdupont Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020) (Million US$)
Table 93. Dowdupont Recent Development
Table 94. Vedanta BioSciences Company Details
Table 95. Vedanta BioSciences Business Overview
Table 96. Vedanta BioSciences Product
Table 97. Vedanta BioSciences Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020) (Million US$)
Table 98. Vedanta BioSciences Recent Development
Table 99. Metabiomics Corporation Company Details
Table 100. Metabiomics Corporation Business Overview
Table 101. Metabiomics Corporation Product
Table 102. Metabiomics Corporation Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020) (Million US$)
Table 103. Metabiomics Corporation Recent Development
Table 104. ViThera Pharmaceuticals Company Details
Table 105. ViThera Pharmaceuticals Business Overview
Table 106. ViThera Pharmaceuticals Product
Table 107. ViThera Pharmaceuticals Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020) (Million US$)
Table 108. ViThera Pharmaceuticals Recent Development
Table 109. MicroBiome Therapeutics Business Overview
Table 110. MicroBiome Therapeutics Product
Table 111. MicroBiome Therapeutics Company Details
Table 112. MicroBiome Therapeutics Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020) (Million US$)
Table 113. MicroBiome Therapeutics Recent Development
Table 114. Osel Company Details
Table 115. Osel Business Overview
Table 116. Osel Product
Table 117. Osel Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020) (Million US$)
Table 118. Osel Recent Development
Table 119. Merck Company Details
Table 120. Merck Business Overview
Table 121. Merck Product
Table 122. Merck Revenue in Human Microbiome Based Drugs and Diagnostics Business (2015-2020) (Million US$)
Table 123. Merck Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Human Microbiome Based Drugs and Diagnostics Market Share by Type: 2020 VS 2026
Figure 2. Therapeutics Features
Figure 3. Diagnostics Features
Figure 4. Global Human Microbiome Based Drugs and Diagnostics Market Share by Application: 2020 VS 2026
Figure 5. Clinical Research Institutes Case Studies
Figure 6. Hospital Case Studies
Figure 7. Surgical Centers Case Studies
Figure 8. Others Case Studies
Figure 9. Human Microbiome Based Drugs and Diagnostics Report Years Considered
Figure 10. Global Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Human Microbiome Based Drugs and Diagnostics Market Share by Regions: 2020 VS 2026
Figure 12. Global Human Microbiome Based Drugs and Diagnostics Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Human Microbiome Based Drugs and Diagnostics Market Share by Players in 2019
Figure 15. Global Top Human Microbiome Based Drugs and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Microbiome Based Drugs and Diagnostics as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Human Microbiome Based Drugs and Diagnostics Revenue in 2019
Figure 17. North America Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Human Microbiome Based Drugs and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
ヒトマイクロバイオーム治療薬の世界市場（～2026年） Human microbiome has co-evolved with humans for centuries, which includes bacteria, viruses, fungi, Achaeans etc. The human microbiome is now one of the fastest growing areas of biology, and is considered as a newly discovered organ with the potential to have a tremendous impact on human health. Mic…- ヒトパラインフルエンザウイルス（HPIV）診断診断の世界市場（～2026年） Human Papillomaviruses (HPV) are members of papillomaviridae family a group of more than 150 related viruses. These are specifically known as papillomaviruses because of some of its types give rise to a wart or papilloma which are benign growths. Some of them are also associated with certain cancers…
- NGSベース診断の世界市場（～2026年） Next generation sequencing (NGS) based diagnostics are the medical devices used for diagnosis of various conditions using advanced generation sequencing platforms. North America is currently leading the market due to the research and innovations and presence of maximum numbers of players. Europe is …
- ヒト呼吸器合胞体ウイルス薬の世界市場（～2026年） Human respiratory syncytial virus (HRSV) is a syncytial virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. A prophylactic medication, palivizumab, can be employed to prevent HRSV in preterm (unde…
- 人物同定（HI）の世界市場（～2026年） Market Analysis and Insights: Global Human Identification Market The global Human Identification market size is projected to reach US$ 38900 million by 2026, from US$ 35770 million in 2020, at a CAGR of 8.1%% during 2021-2026. Global Human Identification Scope and Market Size Human Identification ma…